LYMPHOMAS

Without confirmed clinical benefit in follicular lymphoma and small lymphocytic leukemia, idelalisib's indications for these malignancies were withdrawn from the United States market.

During a Targeted Oncology live event, Grzegorz S. Nowakowski, MD, discussed the case of a patient treated with tafasitamab plus lenalidomide in the second line for diffuse B-cell lymphoma.

Mark Roschewski, MD, discusses how different large cell lymphoma subtypes may respond to different therapies.

E777 is a reformulation of a previous FDA approved agent for CTLC that was pulled from the market voluntarily for improvements.

Tisagenlecleucel failed to improve event-free survival in the second-line setting of relapsed or refractory aggreesve B-cell non-Hodgkin lymphoma versus standard-of-care.

In patients with relapsed/peripheral T-cell lymphoma, the combination of duvelisib plus romidepsin was shown to be highly active.

While Axicabtagene ciloleucel demonstrated favorable efficacy in elderly patients and those with other comorbidities with large B-cell lymphoma, adverse events were common in some of these populations.

Lisocabtagene maraleucel treatment in patients with relapsed or refractory B-cell lymphoma achieves long-lasting responses, study shows.

Phase 3 ZUMA-7 study results indicate that axicabtagene ciloleucel may achieve longer event-free survival compared with standard chemotherapy.

Real-world data on tisagenlecleucel in patients with relapsed/refractory B-cell lymphoma was consistent with the phase 2 JULIET trial, demonstrating favorable efficacy and safety.

Retrospective data from tafasitamab plus lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma correlate with real-world findings.

In patients with relapsed or refractory marginal zone lymphoma, parsaclisib produced a clinical response.

Liso-cel demonstrated meaningful EFS improvement as a second-line therapy in patients with LBCL.

Mark Roschewski, MD, discusses the role Bruton’s tyrosine kinase inhibitor acalabrutinib has in aggressive B-cell lymphoma subgroups.

Richard Anderson, MD, PhD, discusses ways to preserve fertility in patients who are undergoing or have complete treatment for lymphoma.

Venetoclax in combination with EPOCH-R is safe and shows preliminary efficacy in patients with aggressive B-cell lymphoma.

Patrick Connor Johnson, MD, discusses what physicians take into consideration when considering third-line treatment options in diffuse large B-cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma & Myeloma at the University of Texas MD Anderson Cancer Center, discusses the FDA approval of lisocabtagene maraleucel.

Subasumstat was found to have a manageable safety profile along with preliminary anti-tumor activity in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma.

Epcoritamab should be evaluated further after positive phase 1/2 results showing the agent was safe with preliminary antitumor activity.

The FDA is considering an application parsaclisib as treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, and granted priority review for 2 of the 3 indications.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss possible future developments with BTKi as therapy options in B-cell lymphomas.

Drs Shadman and Cohen introduce new data concerning a third-generation BTK inhibitor, pirtobrutinib, and discuss unmet needs in the B-cell malignancy landscape.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, share their preferences regarding BTK-targeted treatment in B-cell malignancies.

Two experts discuss use of ibrutinib and zanubrutinib and data from the ALPINE and ELEVATE-RR trials.